To treat or not to treat with testosterone replacement therapy: A contemporary review of management of late-onset hypogonadism and critical issues related to prostate cancer

Current Urology Reports

Volumn 15, Issue 7, 2014, Pages

  Kava, Bruce R ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Atypical small acinar proliferation; Late onset hypogonadism; Prostate cancer; Prostatic intraepithelial neoplasia; Testosterone replacement therapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

AGE; ANDROGEN THERAPY; ATYPICAL SMALL ACINAR PROLIFERATION; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CARCINOGENESIS; DRUG SAFETY; EVIDENCE BASED PRACTICE; FAMILY HISTORY; FANTASY; HUMAN; HYPOGONADISM; LIBIDO; META ANALYSIS (TOPIC); PATIENT SELECTION; PENIS ERECTION; PRECANCER AND CANCER-IN-SITU; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN BLOOD LEVEL; RACE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SEXUAL BEHAVIOR; SEXUAL FUNCTION; SYSTEMATIC REVIEW (TOPIC); TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; COMPLICATION; DISEASE MANAGEMENT; HORMONE SUBSTITUTION; MALE; PROSTATE TUMOR; TIME;

DISEASE MANAGEMENT; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; PROSTATIC NEOPLASMS; TESTOSTERONE; TIME FACTORS;

EID: 84901527716     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-014-0422-5     Document Type: Review

References (83)

1. •• Huggins C, Hodges CV. Studies on prostatic cancer; the effects of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293-7. Despite the fact that this article was written over 60 years ago, the concept of androgen deprivation to treat prostate cancer remains one of the most important therapeutic discoveries within modern medicine. The article outlines the course of 8 patients with advanced prostate cancer who were treated successfully with surgical orchiectomy. Two of the patients received simultaneous testosterone replacement, which buffered the therapeutic effects of the androgen deprivation. The investigators conclude that testosterone incites prostate cancer to develop and grow, which remains the basis for current FDA guidelines, which indicate that testosterone is contraindicated in men with prostate cancer.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
3. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in the clinical presentation and primary management. J Clin Oncol. 2004;22:2141-9. (Pubitemid 41095147)
4. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86:724-31. (Pubitemid 32207487)
5. •• Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol. 2009;55:121-30. This article is a collaborative effort across several disciplines, represented by the groups within the title. The article provides a comprehensive overview of hypogonadism, including definitions, clinical and laboratory diagnostic criteria, and treatment recommendations.
6. Bhasin S, Cunningham GR, Hayes FJ,Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency symptoms: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2010;95:2536-59.
7. •• Bassil N, Alkaade S, Morley J. The benefits and risks of testosterone replacement therapy. Ther Clin Risk Manag. 2009;5:427-48. This article provides a very complete review of the risks and benefits of TRT. The authors provide an exhaustive list of the various clinical effects of TRT and provide an excellent summary of the clinical trials and their individual contributions to the field. It is an excellent reference.
8. .• Mohr BA, Guay AT, O'Donnell AB, McKinlay JB. Normal bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study. Clin Endocrinol. 2005;62(1):64-73. This is an important article which reports on the epidemiology of hypogonadism using the MMAS. It is an excellent reference and is a tremendous contribution to our current understanding of the prevalence of this disease. (Pubitemid 40175285)
9. Buvat J,Maggi M, Gooren L, Guay AT, Kaufman J, Morgentaler A, et al. Endocrine aspects of male sexual dysfunctions. J Sex Med. 2010;7:1627-56.
10. Corona G, Maggi M. The role of testosterone in erectile dysfunction. Natl Rev Urol. 2010;7:1627-56.
11. Gooren L. Androgens and male aging: current evidence of safety and efficacy. Asian J Androl. 2010;12:136-51.
12. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60(7):762-9. (Pubitemid 43881152)
13. Araujo AB, O'Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004;89:5920-6. (Pubitemid 39628393)
14. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endcorinol Metab. 2002;87:589-98. (Pubitemid 34158223)
15. Liu PY, Beilin J, Meier C, Nguyen TV, Center JR, Leedman PJ, et al. Age related changes in serum testosterone and sex hormone binding globulin in Australian men: longitudinal analysis of two geographically separate regional cohorts. J Clin Endocrinol Metab. 2007;92:3599-603. (Pubitemid 47435341)
16. Orwoll E, Lambert LC, Marshall LM, et al. Testosterone and estradiol in older men. J Clin Endocrinol Metab. 2006;91:1336-44.
17. Yeap BB, Almeida OP, Hyde Z, et al. In men older than 70 years, total testosterone remains stable while free testosterone declines with age. The Health in Men Study. Eur J Endocrinol. 2007;156:585-94. (Pubitemid 46796526)
18. Krithivas K, Yurgalevitch SM, Mohr BA, et al. Evidence that the CAG repeat in the androgen receptor is associated with age related decline in serum androgen levels in men. J Endocrinol. 1999;162:137-42. (Pubitemid 29336364)
19. Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle age men: a 13 year follow-up of former Multiple Risk Factors Intervention Trial participants. Am J Epidemiol. 1997;46:609-17. (Pubitemid 27454548)
20. Wang CW, Alexander G, Berman N, et al. Testosterone replacement therapy improves mood in hypogonadal men: a clinical research center study. J Clin Endocrinol Metab. 1996;81:3578.
21. Gray PB, Singh AB, Woodhouse LJ, et al. Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. J Clin Endocrinol Metab. 2005;90:3838-46. (Pubitemid 41058141)
22. Hajjar RR, Kaiser FE, Morley JE. Outcomes of long-term testosterone replacement in older hypogonadal males; a retrospective analysis. J Clin Endocrinol Metab. 1997;82:3793.
23. Lunenfeld B, Nieschlag E. Testosterone therapy in the aging male. Aging Male. 2007;10:139-53. (Pubitemid 47265837)
24. Gruenenwald DA, Matsumoto AM. Testosterone supplementation therapy for older men: potential benefits and risks. J Am Geriatr Soc. 2003;51:101-15. (Pubitemid 36119943)
25. Morley JE, Perry HM, Kaiser FE, et al. Effect of testosterone replacement therapy in old hypogonadalmales: a preliminary study. J Am Geriatr Soc. 1993;41:149-52. (Pubitemid 23051423)
26. Shabsigh R. The effects of testosterone on the cavernous tissue and erectile function. World J Urol. 1997;15:21-6. (Pubitemid 127769831)
27. Corona G, Petrone L, Fisher AD,Mansani R, Bandini E. Six-month administration of 1% testosterone gel is able to restore erectile function in hypogonadal patients with erectile dysfunction. Arch Ital Urol Androl. 2008;80(3):103-8.
28. Yassin AA, Saad F. Dramatic improvements of penile venous leakage upon testosterone administration. A case report and review of the literature. Andrologia. 2006;38:34-7.
29. •• Shabsigh R, Kaufman JM Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol. 2004;172:659-63. This is an important study in the literature concerning the role of testosterone and erectile function. It is a randomized placebo controlled double-blind parallel-group multicenter study in which 75 hypogonadal patients were randomized to receive daily testosterone gel or placebo, in addition to the use of on-demand sildenafil. Testosterone-treated males had greater improvements in erectile function, orgasmic function, and overall quality of life compared to placebo-treated males.
30. Greco EA, Spera G, Aversa A. Combining testosterone and PDE5 inhibitors in erectile dysfunction: basic rationale and clinical evidence. Eur Urol. 2006;50:940-7. (Pubitemid 44486492)
31. Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, et al. Testosterone andmetabolic syndrome: ameta-analysis study. J Sex Med. 2011;8:272-83.
32. Corona G, Monami M, Rastrelli G, Aversa A, Sforza A, Lenzi A, et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl. 2011;34(6 Pt 1):528-40.
33. Wang C, Cunningham G, Dobs A, Iranmanesh A,Matsumoto AM, Snyder PJ, et al. Long term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89:2085-98. (Pubitemid 38619836)
34. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab. 1999;84:1966-72. (Pubitemid 30647018)
35. Tracz MJ, Sideras K, Bolona ER, Haddad R, Kennedy CC, Uraga MV, et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab. 2006;91:2011-6. (Pubitemid 43854973)
36. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, et al. Systematic review: Comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008;148:197-213. (Pubitemid 351665507)
37. • Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97(6):2050-8. A landmark study in the literature, which provides data supporting that endogenous testosterone levels correlate with longevity in a large population of patients from the VA system.
38. Khaw KT, Dowsett M, Folkerd E, Bingham S,Wareham N, Luben R, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007;116:2694-701. (Pubitemid 350291241)
39. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008;93:68-75.
40. Smith GD, Ben-Shlomo Y, Beswick A, Yarnell J, Lightman S, Elwood P. Cortisol, testosterone, and coronary heart disease: prospective evidence from the Caerphilly study. Circulation. 2005;112(3):332-40. (Pubitemid 41022073)
41. •• Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109-21. This is a must-read for physicians administering testosterone therapy. The study was performed on extremely debilitated individuals who were started on TRT to determine whether it impacted mobility. The study was prematurely terminated due to a disproportionate number of cardiovascular events within the testosterone treatment arm. It is important to note that testosterone levels were not reported in patients, and a large percentage of patients received very high doses of testosterone, which are not usually administered to average patients with LOH.
42. •• Vigen R, O'Donnell CI, Baron AE, Grunwald GK, Maddox TM, Bradley SM, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829-36. This is another "must-read" for practitioners who prescribe testosterone. This retrospective cohort study evaluated men with low testosterone levels who underwent coronary artery angiography in the VA system between 2005 and 2011 were. The study found that the risk of myocardial infarction, stroke, and death was higher in hypogonadal men who were started on TRT than in those who were not treated. There are many controversies and questions regarding the statistical models employed in this study. The raw numbers seem to indicate that there were more adverse events in the untreated group of hypogonadal veterans, but with very complicated statistical weighting, the results are reversed. Because this article was just published,many letters to the editor are expected, so stay tuned....
43. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005;60(11):1451-7. (Pubitemid 41798454)
44. Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men a systematic review and meta-analysis of randomized, placebo-controlled trials.Mayo Clin Proc. 2007;82:29-39. (Pubitemid 46036319)
45. • Fernandez-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, et al. Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95:2560-75. An important level 1 analysis of the current literature that comprehensively evaluates the risks and benefits of TRT. While prior meta-analyses were equally important at the time (references 45, 46), this represents the most current meta-analysis, and therefore it is highlighted.
46. • Corona G, Rastrelli G, Forti G, Maggi M. Update in testosterone therapy for men. J Sex Med. 2011;8:639-54. Provides an excellent overview of the current state of TRT.
47. Jin B, Conway AJ, Handelsman DJ. Effects of androgen deficiency and replacement on prostate zonal volumes. Clin Endocrinol. 2001;54:437-45. (Pubitemid 34204179)
48. Iehlé C, Radvanyi F, Gil Diez de Medina S, et al. Differences in steroid 5 alpha-reductase iso-enzymes expression between normal and pathological human prostate tissue. J Steroid Biochem Mol Biol. 1999;68(5-6):189-95. (Pubitemid 29290654)
49. Welén K, Damber JE. Prostate diseases-role of sex steroids and their inhibitors. Best Pract Res Clin Endocrinol Metab. 2011;25:355-67.
50. McConnell JD, Brukewitz R,Walsh P, et al. The effect of finasteride on the risk for acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group. N Engl J Med. 1998;338(9):557-63. (Pubitemid 28114643)
51. McConnell JD, Roehrborn CG, Bautista OM, et al. The long term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387-98. (Pubitemid 37542987)
52. Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123-31.
53. •• Feneley MR, Carruthers M. Is testosterone treatment good for the prostate: study of the safety during long-term treatment. J Sex Med. 2012;9:2138-49. This is an important contribution to a field that has too many short term outcomes reported with TRT. IN this article, the authors provide follow up of 1365 men who were placed on TRT, with some men monitored for up to 20 years. Long term safety of TRT is reported. Additionally, the risks of malignancy in these patients is no more than would be expected for the general population of eugonadal men not treated with TRT.
54. •• Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner M. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory. J Urol. 2011;186:1005-11. Another important study in the field, which provides prospective follow up of hypogonadal men on TRT. Serum PSA levels increased more profoundly in those men with T levels of 250 ng/dl at baseline than in those with levels above this at baseline. Overall, the latter group did not demonstrate a statistically significant increase in the serum PSA following TRT, an important fact to understand when treating men with TRT.
55. •• Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009;55:310-21. The authors outline one of the most important concepts that underlie how we currently approach TRT. The saturation model is discussed above, and is a very important contribution to andrology and oncology.
56. Zitzmann M, Mattern A, Hanisch J, Gooren L, Jones H, Maggi M. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med. 2013;10:579-88.
57. Coward RM, Simhan J, Carson III CC. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. BJU Int. 2008;103:1179-83.
58. Raynaud JP, Gardette J, Rollet J, Legros JJ. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment. BJU Int. 2013;111(6):880-90.
59. • Endogenous Hormones and Prostate Cancer Collaborative Group. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100:170-83. This article is an extremely important contribution to the field. The authors provide an excellent meta-analysis that confirms that there is little association between serum testosterone levels and prostate cancer risk.
60. Gershman B, Shui IM Stampfer M, Platz EA, Gann PH, Sesso HL, et al. Prediagnostic circulating sex hormones are not associated with mortality for men with prostate cancer. Eur Urol 2014;65(4):683-9.
61. Muller RL, Gerber L,Moreira DM, Andriole G, Castro-Santamaria R, Freedland SJ. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. Eur Urol 2012;62(5):757-64.
62. Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology. 2006;68:1263-7. (Pubitemid 44880344)
63. Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high-grade prostate cancer? J Urol. 2000;163:824-7. (Pubitemid 30091624)
64. Mearini L, Costantini E, Zucchi A, Mearini E, Bini V, Cottini E, et al. Testosterone levels in benign prostatic hypertrophy and prostate cancer. Urol Int. 2008;80:134-40. (Pubitemid 351440505)
65. Garcia-Cruz E, Piqueras M, Huguet J, Peri L, Izquierdo L, Musquera M, et al. Low testosterone levels predict prostate cancer in re-biopsy in patients with high grade prostatic intraepithelial neoplasia. BJU Int. 2012;10(11 Pt B):E541-6.
66. Gooren LJ, Behre HM. Diagnosing and treating testosterone deficiency in different parts of the world: changes between 2006 and 2010. Aging Male. 2012;15:22-7.
67. Marks LS, Mazer NA, Mostaghel E, et al. Effects of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296(19):2351-61. A very interesting study that evaluates serum and intracellular prostate changes in men placed on TRT. The study provides excellent evidence that TRT does not increase intraprostatic T or DHT levels, and does not appear to incite benign or malignant growth within the short term. (Pubitemid 44749363)
68. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350:482-92. (Pubitemid 38133769)
69. Shabsigh R, Crawford ED, Nehra A, Slawin KM. Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. Int J Impot Res. 2009;21:9-23.
70. Bhasin S, Singh A, Phong Mac R, Carter B, Lee MI, Cunningham G. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations or a standardized monitoring plan. J Androl. 2003;24(3):299-311. (Pubitemid 39571784)
71. •• Kaplan AL, Hu JC. Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes. Urology. 2013;82:321-6. An important study in which the authors link SEER and Medicare data; a total of 2,237 men with prostate cancer had received TRT sometime prior to diagnosis. TRT did not appear to impact the aggressiveness associated with prostate cancer and did not affect overall or disease-specific mortality.
72. Coward R, Simhan J, Carson III CC. Racial differences in hypogonadal improvement and prostate specific antigen levels in hypogonadalmen treatedwith testosterone replacement therapy. Int Braz J Urol. 2010;36(6):700-9.
73. Bostwick DG, Qian J, Frankel K. The incidence of high grade prostatic intraepithelial neoplasia in needle biopsies. J Urol. 1995;154:1791-4.
74. Davidson D, Bostwick DG, Qian J, Wollan PC, Oesterling JE, Rudders RA, et al. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies.
75. Rhoden EL, Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol. 2003;170:2348-51. (Pubitemid 37413994)
76. Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007;109:536-41. (Pubitemid 46190961)
77. Morales A, Black AM, Emerson LE. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations. BJU Int. 2009;103:62-4.
78. Pastuszak AW, Pearlman AM, Godoy G, Miles BJ, Lipshultz LI, Khera M. Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res. 2013;25:24-8.
79. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004;172:920-2. (Pubitemid 39096423)
80. Agarwal PK, Olefein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol. 2005;173:533-6.
81. Khera M, Grober ED, Najari B, et al. Testosterone replacement therapy following radical prostatectomy. J Sex Med. 2009;6:1165-70.
82. Pastuszak AW, Pearlman AM, Lai WS, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013;190:639-44.
83. •• Morgentaler A, Lipshultz LI, Bennett R, Sweeney M, Avila D, Khera M. Testosterone therapy in men with untreated prostate cancer. J Urol. 2011;185:1256-61. This is the first article of its kind, in which untreated prostate cancer patients received TRT. It is a case series, with no control group, which diminishes its scientific impact. Nevertheless, it has provided the field with a basis for further study of TRT in patients with active prostate cancer.